(4S)-2,2,4,5-tetramethylhexan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4S)-2,2,4,5-tetramethylhexan-3-one
• 化学式: C₁₀H₂₀O
• 分子量: 156.26
• InChiKey: AYGMAUFUPIHQQG-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20150023913A1

  公开（公告）日：2015-01-22

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents
  申请人：METHYLGENE INC.

  公开号：US20140081017A1

  公开（公告）日：2014-03-20

  The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds. The compositions of the invention are comprised of a combination of a histone deacetylase inhibitor, or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, agricultural formulation, prodrug or complex thereof, and an antifungal agent, the histone deacetylase inhibitor being a compound of Formula (I):

  本发明涉及用于选择性治疗真菌感染的组合物和方法。更具体地，本发明涉及化合物、其组合物以及用于增强真菌对抗真菌化合物敏感性的方法。本发明的组合物由组成，其中组脱乙酰酶抑制剂的组合物，或N-氧化物、水合物、溶剂化合物、药用可接受盐、农药配方、前药或其复合物，以及抗真菌剂，其中组脱乙酰酶抑制剂为式(I)的化合物：
• DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20160068566A1

  公开（公告）日：2016-03-10

  The present invention concerns a compound of following formula (I): where: —R 1 is H or OH, —R 2 is a (C 1 -C 6 )alkyl, COOH, COO—((C 1 -C 6 )alkyl) or thiazolyl group, —R 3 is H or a (C 1 -C 6 )alkyl group, and —R 4 is: ▪ a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR 5 R 6 , ▪ —(CH 2 CH 2 X 1 )(CH 2 CH 2 X 2 ) a2 (CH 2 CH 2 X 3 ) a3 (CH 2 CH 2 X 4 ) a4 (CH 2 CH 2 X 5 ) a5 R 7 , ▪ an aryl-(C 1 -C 8 )alkyl group substituted by one or more groups chosen from among OH and NR 9 R 10 groups, or ▪ a heterocycle-(C 1 -C 8 )alkyl group optionally substituted by one or more groups chosen from among (C 1 -C 6 )alkyl, OH and NR 12 R 13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.

  本发明涉及以下式（I）的化合物： 其中： —R1是H或OH， —R2是（C1-C6）烷基，COOH，COO-（（C1-C6）烷基）或噻唑基， —R3是H或（C1-C6）烷基，以及 —R4是： ▪ 直链或支链、饱和或不饱和的碳数为1到8的烃基，被一个或多个从OH和NR5R6中选择的基团取代， ▪ -（CH2CH2X1）（CH2CH2X2）a2（CH2CH2X3）a3（CH2CH2X4）a4（CH2CH2X5）a5R7， ▪ 被一个或多个从OH和NR9R10基团中选择的基团取代的芳基-(C1-C8)烷基，或 ▪ 可选地被一个或多个从（C1-C6）烷基、OH和NR12R13基团中选择的基团取代的杂环-(C1-C8)烷基， 以及其在癌症治疗中的应用、含有该化合物的制药组合物以及其制备方法的使用。
• Combinations of Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160158200A1

  公开（公告）日：2016-06-09

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• US9770439B2
  申请人：——

  公开号：US9770439B2

  公开（公告）日：2017-09-26